Trial · NCT04005352
Results by group192
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 192
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Distribution of the Last Interval With no Disease Activity up to Week 32 - Study Eye | Brolucizumab 6 mg | 12 weeks | 141 | Participants | |
| Distribution of the Last Interval With no Disease Activity up to Week 32 - Study Eye | Aflibercept 2 mg | 12 weeks | 73 | Participants | |
| Distribution of the Last Interval With no Disease Activity up to Week 32 - Study Eye | Brolucizumab 6 mg | 8 weeks | 131 | Participants | |
| Distribution of the Last Interval With no Disease Activity up to Week 32 - Study Eye | Aflibercept 2 mg | 8 weeks | 147 | Participants | |
| Distribution of the Last Interval With no Disease Activity up to Week 32 - Study Eye | Brolucizumab 6 mg | 4 weeks | 94 | Participants | |
| Distribution of the Last Interval With no Disease Activity up to Week 32 - Study Eye | Aflibercept 2 mg | 4 weeks | 148 | Participants | |
| Average Change From Baseline at Week 28 and Week 32 in Best-corrected Visual Acuity (BCVA) - Study Eye | Brolucizumab 6 mg | 5.2 | Standard Error 0.51 | Scores on a scale | |
| Average Change From Baseline at Week 28 and Week 32 in Best-corrected Visual Acuity (BCVA) - Study Eye | Aflibercept 2 mg | 5.1 | Standard Error 0.51 | Scores on a scale | |
| Distribution of the Last Interval With no Disease Activity up to Week 64 - Study Eye | Brolucizumab 6 mg | 16 Weeks | 104 | Participants | |
| Distribution of the Last Interval With no Disease Activity up to Week 64 - Study Eye | Aflibercept 2 mg | 16 Weeks | 45 | Participants | |
| Distribution of the Last Interval With no Disease Activity up to Week 64 - Study Eye | Brolucizumab 6 mg | 12 Weeks | 82 | Participants | |
| Distribution of the Last Interval With no Disease Activity up to Week 64 - Study Eye | Aflibercept 2 mg | 12 Weeks | 88 | Participants | |
| Distribution of the Last Interval With no Disease Activity up to Week 64 - Study Eye | Brolucizumab 6 mg | 8 Weeks | 95 | Participants | |
| Distribution of the Last Interval With no Disease Activity up to Week 64 - Study Eye | Aflibercept 2 mg | 8 Weeks | 81 | Participants | |
| Distribution of the Last Interval With no Disease Activity up to Week 64 - Study Eye | Brolucizumab 6 mg | 4 Weeks | 85 | Participants | |
| Distribution of the Last Interval With no Disease Activity up to Week 64 - Study Eye | Aflibercept 2 mg | 4 Weeks | 154 | Participants | |
| Distribution of the Maximal Intervals With no Disease Activity up to Week 64 - Study Eye | Brolucizumab 6 mg | 16 Weeks | 117 | Participants | |
| Distribution of the Maximal Intervals With no Disease Activity up to Week 64 - Study Eye | Aflibercept 2 mg | 16 Weeks | 57 | Participants | |
| Distribution of the Maximal Intervals With no Disease Activity up to Week 64 - Study Eye | Brolucizumab 6 mg | 12 Weeks | 96 | Participants | |
| Distribution of the Maximal Intervals With no Disease Activity up to Week 64 - Study Eye | Aflibercept 2 mg | 12 Weeks | 92 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04005352/results